Nitroglycerin
As of the edition of 20 October 2026, Nitroglycerin is a small molecule: marketed, first approved in 1972 (CA); acts on GUCY1B1 and GUCY1B2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1984
- Kind
- Small molecule
- Brand name
- Nitrostat
- First approved
- 31 December 1972 (CA)
- Approvals on record
- 36 in 3 regions
- Holder of the most recent approval
- G Pohl Boskamp; 16 holders in all
- Registered trials
- 112, 8 stopped early
- Disease areas
- Heart and blood vessels; Urinary and reproductive; Nervous system; Cancer; Digestive system; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 38 | 22 | 5 | 4 |
| Phase 1 | 13 | 7 | 3 | 0 |
| Phase 2 | 22 | 12 | 2 | 2 |
| Phase 3 | 17 | 14 | 1 | 1 |
| Phase 4 | 22 | 11 | 2 | 1 |
| All trials | 112 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sanofi | Later holder | 1982 to now |
| G. Pohl-Boskamp | Later holder | 1983 to now |
| Baxter Healthcare | Later holder | 1989 to now |
| Novartis | Later holder | 1996 to now |
| Pfizer | Acquired holder and Later holder | 2000 to now |
| G Pohl Boskamp | Acquired holder and Later holder | 2003 to now |
| Rorer Pharmaceutical Corp Sub Rorer | Acquired holder | 2003 to now |
| Pohl Boskamp | Acquired holder | 2011 to now |
| Uspharma | Acquired holder | 2017 to now |
| Evus Health Solutions | Acquired holder | 2019 to now |
| Viatris | Acquired holder | 2022 to now |
| AbbVie | Acquired holder | 2023 to now |
| Abbott | Earlier holder |